Kraton Corporation

Kraton — Kraton Performance Polymers — Investor Presentation (October 2015)

38 slides from Kraton's investor presentation, Oct 5, 2015

  1. Slide 1: Kraton Performance Polymers, Inc. Investor Overview October 2015

    Kraton Performance Polymers, Inc. Investor Overview October 2015

  2. Slide 2: Forward-Looking Statement Disclaimer

    Forward- Looking Statement Disclaimer This presentation includes forward-looking statements that reflect our plans, beliefs, expectations and current views with respect to, among other things, future events and financial performance. Forward-looking statements are often characterized by the use of w

  3. Slide 3: GAAP Disclaimer

    GAAP Disclaimer This presentation includes the use of both GAAP and non-GAAP financial measures. The non-GAAP financial measures are EBITDA, Adjusted EBITDA, Adjusted Gross Profit and Adjusted Net Income attributable to Kraton (or earnings per share). Tables included in this presentation and our ear

  4. Slide 4: Kraton is the Global Leader in the SBC Industry

    Kraton is the Global Leader in the SBC Industry N. America 33% S. America 5% Asia 27% EMEA 35%  Original inventor of SBC chemistry 50 years ago, with leading market share positions in the end use markets we serve  Designer and manufacturer of custom SBC and compound solutions with the broadest por

  5. Slide 5: Kraton's Market-leading Worldwide Footprint

    Kraton’s Market-leading Worldwide Footprint Belpre, Ohio Manufacturing Facility Houston, Texas Global Headquarters Innovation Center Paulinia, Brazil Manufacturing Facility Innovation Center Mont St. Guibert, Belgium Technical Service Office Wesseling, Germany Manufacturing Facility Kashima, Japan M

  6. Slide 6: Kraton's Strategic Focus

    Kraton’s Strategic Focus 6 Investor Overview Ongoing implementation of Kraton’s “three-part” strategy  Cost competitiveness  Deliver $70 million of cost outs by 2018  Achieve $50 million working capital benefit through complexity reduction  Organic growth  Market-facing organization creates dee

  7. Slide 7: Three-part Strategy Focused On Growth And Improved Profitability

     Revised approach to the market  Rebalanced R&D strategy and portfolio  Compelling and strategic acquisitions to improve cost position and access new markets  Manufacturing optimization and investments in asset productivity  Broad complexity reduction and overhead efficiency effort Three-part S

  8. Slide 8: Improvement in Our Cost Position Through Multiple Initiatives

    Improvement in Our Cost Position Through Multiple Initiatives By 2018 we expect: $70M in annual run rate cost savings and $50M of working capital reduction Manufacturing Optimization Asset Productivity Overhead Efficiency  Expand USBC at Berre and leverage Mailiao to optimize global HSBC  Belpre b

  9. Slide 9: A New Approach To The Market and A Rebalanced R&D Strategy

    Revised market approach Rebalanced Innovation Strategy A New Approach To The Market and A Rebalanced R&D Strategy We expect this work to drive our organic growth through further portfolio shift and deeper customer relationships 9 Investor Overview

  10. Slide 10: We Are Well On Our Way To Delivering Planned Cost Reductions

    We Are Well On Our Way To Delivering Planned Cost Reductions Remaining cost actions 2015 includes:  $4M from Belpre boiler project ($10M annualized)  $8M of other manufacturing cost improvements  $6M selling, administrative and research cost improvements 10 Investor Overview

  11. Slide 11: Acquisition of Arizona Chemical

    Acquisition of Arizona Chemical  Industry leading supplier of specialty chemicals and high-value products derived primarily from non-hydrocarbon, renewable resources  Extremely complementary to Kraton’s existing business with greater than 50% of Arizona’s sales into common end markets  Similar bu

  12. Slide 12: Transaction Highlights

    Transaction Highlights  $1.37 billion in cash funded with committed debt facilities  7.4x June 2015 TTM Adjusted EBITDA, 5.5x with synergies a) In the first year following the transaction, the EPS accretion, currently estimated to be $1.40 per share, includes the net operating loss synergy amounti

  13. Slide 13: Arizona is a Global Leader in Specialty Chemicals

     Headquartered in Jacksonville, FL and Almere, Netherlands  Leading converter of Crude Tall Oil (“CTO”) to value added specialty chemicals  CTO is a renewable resource and a by-product of the kraft papermaking process  9 manufacturing plants in Europe and North America, 3 science & technology ce

  14. Slide 14: Arizona Has a Strong Competitive Position

    Arizona Has a Strong Competitive Position  #1 processor of pine chemicals in the world  #1 global producer of Rosins, Tall Oil Fatty Acids (“TOFA”) and derivatives  Broad product portfolio  #1 global supplier of pine-based tackifiers  #1 global supplier of pine-based pavement markers  Leading

  15. Slide 15: Arizona's Business is Highly Complementary to Kraton's

    Arizona’s Business is Highly Complementary to Kraton’s Adhesives  Common customers, markets and applications  Kraton: Diapers, tapes and labels  Arizona: Rigid packaging, tapes and labels Roads & Construction  Common customers, markets and applications  Kraton: Asphalt modification, road markin

  16. Slide 16: Arizona Historical Financial Summary

    Arizona Historical Financial Summary $ millions 2012 2013 2014 TTM 06/30/15 Volume (kT) 657 676 620 612 Revenues 1,042 992 938 863 Adjusted EBITDA 241 205 192 184 % margin 23% 21% 20% 21% Capex 34 47 35 38 Adjusted EBITDA less Capex 207 158 157 146 Quarterly Adjusted EBITDA ($ millions)  Consistent

  17. Slide 17: Capital Structure

    Capital Structure  Expected closing leverage of 4.6x June 2015 TTM Adjusted EBITDA reducing to approximately 3.0x by end 2017  Post-closing, total Kraton pro-forma indebtedness of $1.78 billion  $1.35 billion covenant-lite term loan  $425 million senior unsecured notes  $250 million ABL facilit

  18. Slide 18: Cost and Operational Improvement Opportunities

    Cost and Operational Improvement Opportunities  Leverage expertise within Arizona and Kraton to:  Reduce energy consumption  Lower maintenance spending  Improve productivity and yields  Optimize supply chain network to lower overall logistics costs  Corporate and G&A overhead  Improvements ex

  19. Slide 19: Pro forma Kraton: TTM June 2015 Financial Summary

    Pro forma Kraton: TTM June 2015 Financial Summary $ millions Kraton Arizona PF Kraton Change Revenues 1,112 863 1,976 +1.8x Adjusted EBITDA 146 184 395(a) +2.7x % Margin 13.1% 21.3% 20.0% +690 bps CapEx 67(b) 38 105(b) % of Sales 6.0% 4.4% 5.3% Adjusted EBITDA – CapEx 79 146 290(a) +3.7x % Margin 7.

  20. Slide 20: Arizona's Broad Product Portfolio Serves Growth Markets

    Arizona’s Broad Product Portfolio Serves Growth Markets $ millions ADHESIVES ROADS & CONSTRUCTION TIRES CHEMICAL INTERMEDIATES Revenue(a) % Total 265 31% 55 6% 42 5% 501 58% Key Products  Rosin esters & dispersions  Terpenes & derivatives  Rosin esters  TOFA & derivatives  AMS resins  Terpenes

  21. Slide 21: Cariflex

    Cariflex 13% Specialty Polymers 33% Perf. Products 54%  Sales volume increased 26.0%, largely driven by higher sales into surgical glove applications  Excluding a $2.5 million negative effect from currency fluctuations, revenue growth of 22.0%, despite lower raw material costs  Cariflex represent

  22. Slide 22: Cariflex - Sample End Market Applications

    CariflexTM - Sample End Market Applications Medical Applications  Surgical gloves and condoms  Medical catheters  Medical tube connectors  Needle shields  Stoppers for IV bags and medical bottles Industrial Applications  Cold seal adhesives for food packaging  Coatings for printed circuit boa

  23. Slide 23: Specialty Polymers

    Specialty Polymers Products are based upon HSBC chemistry  Accounts for 33% of TTM revenue at 6/30/2015 Compete against a variety of chemical and non-chemical alternatives including PVC and thermoplastic elastomers Used to impart specific performance characteristics in end use products where produc

  24. Slide 24: Specialty Polymers – Sample End Market Applications

    Specialty Polymers – Sample End Market Applications Personal Care Provides stretch in elastic films used in:  Diapers  Adult incontinence products and hygiene applications Polymod  Used by compounding and formulating industry to modify materials for a wide variety of consumer and industrial produ

  25. Slide 25: Performance Products

    Performance Products Products based upon USBC chemistry  Accounts for 54% of TTM revenue at 6/30/2015 Products compete with acrylics, silicones, solvent-based rubber systems and thermoplastic polyolefin elastomers  Provides adhesion and bond strength, consistent performance in adhesive and coating

  26. Slide 26: Performance Products - End Market Applications

    Performance Products - End Market Applications Packaging & Industrial Adhesives Modify tack and shear properties of adhesives in:  Tapes  Labels Personal Care In personal care and hygiene products:  Elastic film and construction adhesives Industrial Used to for viscosity modification and adhesive

  27. Slide 27: Kraton Portfolio Overview

    Kraton Portfolio Overview Revenue by Geography 6/30/2015 TTM Revenue by Product Group 6/30/2015 TTM 27 46% 43% 54% 57% TTM June 2014 TTM June 2015 Portfolio Composition Standard Innovation & DifferentiatedNorth America 33% Europe 35% Asia 27% South America 5% Cariflex 13% Specialty Polymers 33% Perf

  28. Slide 28: Appendix October 2015

    Appendix October 2015 28 Investor Overview

  29. Slide 29: Reconciliation of Gross Profit to Adjusted Gross Profit

    Reconciliation of Gross Profit to Adjusted Gross Profit ($ in millions) Q1'12 Q2'12 Q3'12 Q4’12 Q1’13 Q2’13 Q3’13 Q4’13 Q1'14 Q2'14 Q3'14 Q4’14 Q1’15 Q2’15 Gross Profit @ FIFO $ 75.5 $ 73.5 $ 42.8 $ 39.7 $ 59.9 $ 59.9 $ 47.5 $ 58.6 $ 57.1 $ 72.1 $ 63.8 $ 44.1 $ 46.6 $ 47.4 FIFO to ECRC (3.4 ) (14.0

  30. Slide 30: GAAP and Non-GAAP Statement of Operations – Q2 2015

    GAAP and Non-GAAP Statement of Operations – Q2 2015 ($ in thousands, except per share amounts) Three Months Ended June 30, 2015 As Reported Other Adjustments FIFO TO ECRC Adjustment Adjusted Revenue $ 255,908 $ — $ — $ 255,908 Cost of goods sold 208,472 119 (a) (5,810 ) 202,781 Gross profit 47,436 (

  31. Slide 31: GAAP and Non-GAAP Statement of Operations – Q2 2014

    GAAP and Non-GAAP Statement of Operations – Q2 2014 ($ in thousands, except per share amounts) Three Months Ended June 30, 2014 As Reported Other Adjustments FIFO TO ECRC Adjustment Adjusted Revenue $ 323,767 $ — $ — $ 323,767 Cost of goods sold 251,687 (67 ) (a) 4,300 255,920 Gross profit 72,080 67

  32. Slide 32: Six Months Ended June 30, 2015 Statement of Operations

    Six Months Ended June 30, 2015 As Reported Other Adjustments FIFO TO ECRC Adjustment Adjusted Revenue $ 517,337 $ — $ — $ 517,337 Cost of goods sold 423,340 247 (a) (39,218 ) 384,369 Gross profit 93,997 (247 ) 39,218 132,968 Operating expenses: Research and development 15,748 — — 15,748 Selling, gen

  33. Slide 33: Six Months Ended June 30, 2014 Statement of Operations

    Six Months Ended June 30, 2014 As Reported Other Adjustments FIFO TO ECRC Adjustment Adjusted Revenue $ 635,423 $ — $ — $ 635,423 Cost of goods sold 506,270 (12,971 ) (a) 8,324 501,623 Gross profit 129,153 12,971 (8,324 ) 133,800 Operating expenses: Research and development 16,296 — — 16,296 Selling

  34. Slide 34: Reconciliation of Net Income and EPS to Adjusted Net Income and EPS

    Reconciliation of Net Income and EPS to Adjusted Net Income and EPS ($ in thousands, except per share amounts) Three Months Ended June 30, 2015 Three Months Ended June 30, 2014 Income (Loss) Before Income Tax Income Taxes Noncontrolling Interest Diluted EPS Income Before Income Tax Income Taxes Nonc

  35. Slide 35: Reconciliation of Net Income to EBITDA and Adjusted EBITDA

    Reconciliation of Net Income to EBITDA and Adjusted EBITDA ($ in thousands) (a) Severance expenses, professional fees and other restructuring related charges which are primarily recorded in selling, general and administrative expenses in 2015 and primarily in cost of goods sold in 2014. (b) Charges

  36. Slide 36: Kraton - Reconciliation of Consolidated Net Income (Loss) to EBITDA and Adjusted EBITDA

    Kraton - Reconciliation of Consolidated Net Income (Loss) to EBITDA and Adjusted EBITDA Note: Table may not foot due to rounding. a) Receipt from LyondellBasell in settlement of disputed charges, which is recorded in cost of goods sold. b) Charge associated with resolution of a property tax dispute

  37. Slide 37: Arizona - Reconciliation of Consolidated Net Income (Loss) to EBITDA and Adjusted EBITDA

    Arizona - Reconciliation of Consolidated Net Income (Loss) to EBITDA and Adjusted EBITDA Note: Table may not foot due to rounding. a) Charges associated with the termination of an employee defined benefit pension plan including curtailment costs and cash costs related to the termination of the plan.

  38. Slide 38: Kraton + Arizona - Pro-Forma Combined Calculation of Net Leverage at Transaction Close

    Kraton + Arizona - Pro-Forma Combined Calculation of Net Leverage at Transaction Close Note: Table may not foot due to rounding. a) Adjustment to normalize turnaround costs subject to a cap of $7.5 million. b) Adjustment to attain the run-rate cost savings for implemented actions. c) Represents the

Kraton Performance Polymers — Investor Presentation (October 2015) on 6ix